Alx Oncology Holdings Inc.
ALXO Nasdaq
SEC CIK 1810182
Follow Alx Oncology
Weekly email: filings, results
Net income
−$21.8M
+1.4% vs same quarter last year
EPS, diluted
−$0.15
+63.4% vs same quarter last year
Operating cash flow
−$14.7M
+13.8% vs same quarter last year
Operating income
−$22.9M
−1.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$101.7M |
| FY24 | - | −$134.9M |
| FY23 | - | −$160.8M |
| FY22 | $0 | −$123.5M |
| FY21 | $0 | −$83.5M |
| FY20 | $1.2M | −$45.7M |
| FY19 | $4.8M | −$19.2M |
| FY18 | $2.1M | −$13.7M |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | −3694% | −3869.7% |
| FY19 | −400% | −401.2% |
| FY18 | −662% | −664.3% |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$84.4M |
| FY24 | −$122.4M |
| FY23 | −$131.6M |
| FY22 | −$90.7M |
| FY21 | −$68.8M |
| FY20 | −$38.3M |
| FY19 | −$14.6M |
| FY18 | −$13.8M |
| FY17 | - |
- Alx Oncology
- Healthcare median
Show the numbers
| Year | Alx Oncology | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | −3869.7% | −62.2% |
| FY19 | −401.2% | −46.3% |
| FY18 | −664.3% | −49.6% |
| FY17 | - | −45.9% |